Cerulea Clinical Trials

Science and Research


A Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD).

This trial is undertaken by the Centre for Eye Research Australia.



This study aims to assess a new implant called OTX–TKI, which contains the study drug axitinib.

The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.

The OTX-TKI implant is injected into the vitreous of the eye (the jelly-like substance that fills the eyeball), and monitored until the implants slowly break down and are eventually cleared from the eye.

Regular visits are scheduled for a minimum of 9 months from the implant date.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.